Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. The Companyâ€™s pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. The development priorities in oncology are the completion of Phase 3 trials with perifosine in colorectal cancer (CRC) and in multiple myeloma (MM), as well as the further advancement of AEZS-108, for which it has completed a Phase 2 trial in advanced endometrial and advanced ovarian cancer. Its pipeline also encompasses other earlier-stage programs in oncology. AEZS-112, which is an oral anticancer agent, which includes three mechanisms of action (tubulin, topoisomerase II and angiogenesis inhibition) has completed a Phase 1 trial in advanced solid tumors and lymphoma.
|David Dodd||Chairman of the Board, President, Chief Executive Officer|
|Dennis Turpin||Chief Financial Officer, Senior Vice President|
|Richard Sachse||Senior Vice President, Chief Scientific Officer, Chief Medical Officer|
|Jude Dinges||Chief Commercial Officer, Senior Vice President|
|Philip Theodore||Senior Vice President, Chief Administrative Officer, Corporate Secretary|